## SPEEDS: A Portable Serological Testing Platform for Rapid Electrochemical Detection of SARS-CoV-2 Antibodies

Ran Peng<sup>1†</sup>, Yueyue Pan<sup>1†</sup>, Zhijie Li<sup>2</sup>, Zhen Qin<sup>1</sup>, James M. Rini<sup>2,3</sup>, Xinyu Liu<sup>1,4\*</sup>

<sup>1</sup> Department of Mechanical and Industrial Engineering, University of Toronto, 5 King's College

Road, Toronto, Ontario, Canada M5S 3G8

<sup>2</sup> Department of Molecular Genetics, University of Toronto, 361 University Ave, Toronto, Ontario,

Canada M5G 1M1

<sup>3</sup> Department of Biochemistry, University of Toronto, 361 University Ave, Toronto, Ontario,

Canada M5G 1M1

<sup>4</sup> Institute of Biomaterials and Biomedical Engineering, University of Toronto, 164 College Street, Toronto, Ontario, Canada M5S 3G9

\*Corresponding author: Xinyu Liu, phone: +1-416-946-0558. e-mail: xyliu@mie.utoronto.ca.

<sup>†</sup>These authors contributed equally to this work.



**Fig. S1.** Fabrication of the three-electrode electrochemical immunosensor. (a) A 3D model showing the process of PDMS barrier patterning. The reaction zone was defined by a wax-printed cycle and a thin PDMS line barrier was printed at the intersection of the circular WE zone and its 'tail' connection. (b) A photograph of 96 immunosensors fabricated on a letter-sized PET film.



**Fig. S2.** (a) Four immunosensors stored in a nitrogen-infused airtight bag with desiccant inside. (b) The experimental setup for clinical sample testing inside a biosafety cabinet.



**Fig. S3.** Experimental determination of the incubation and washing conditions for SA immobilization on the WE. (a) The schematic of using biotinylated 5-fluorescein for testing the SA immobilization efficiency. The SA was absorbed on the WE and blocked by blocking proteins, and the fluorescein was captured by the SA and examined by a fluorescence microscope. (b-f) The fluorescence images of WEs, incubated with SA for (b) 1 h, (c) 4 h, (d) 8 h, (e) 12 h, and (f) 24 h, then labelled with biotin-5-fluorescein conjugate, and finally washed with PBS for three times. (g) Average fluorescence intensity of the WEs after SA incubation for different durations (n = 4). (h) The fluorescence intensity of the WEs after SA incubation of 12 h, treated with biotin-5-fluorescein conjugate, and washed for twice, three and five times (n=4).



**Fig. S4.** Calibration curves of CR3022 IgG detection using spiked PBS on immunosensors prepared with four different concentrations of the biotinylated RBD capture probe (n=4). The variations of the CA current from different concentrations of RBD can be seen in the high concentration range (> 600 ng/mL).



**Fig. S5.** The cross-reaction testing of anti-SARS-CoV-2 IgG and IgM detection in PBS (n=5). (a) The cross-reactivity data of CR3022 IgG detection using total human IgG as the interference protein.  $*p=4.72\times10^{-8}$ . (b) The cross-reactivity data of CR3022 IgG detection using CR3022 IgM as the interference protein. \*\*p-value=2.29×10<sup>-6</sup>; (c) The cross-reactivity data of CR3022 IgM detection using CR3022 IgG as the interference protein. \*\*p-value=1.06×10<sup>-7</sup>.

Material	Cost for a single test (USD)
PET film	0.00718
Protection film	0.00124
Airtight bags	0.0259
Desiccants	0.00797
Carbon ink	0.00957
Ag/AgCl ink	0.120
PDMS	0.0000167
H <sub>2</sub> SO <sub>4</sub>	0.000360
Streptavidin	0.391
Biotinylated RBD	1.50
<b>Blocking reagent for ELISA</b>	0.00219
Immunoassay stabilizer	0.0174
ALP-conjugated goat anti-human IgG/	0.0171
ALP-conjugated goat anti-human IgM	0.01/1
pAPP	0.00128
Total cost	2.10

## **Table S1.** The cost breakdown of one test.

**Table S2** Fitting parameters. The calibration curves under two detection modes are fitted with the Boltzmann model:  $y = f(x) = \frac{A_1 - A_2}{1 + e^{(x - x_0)/dx}} + A_2$ , where y is the CA current in amperes (A) and x is the concentration of antibody in ng/mL.

	<i>A</i> 1	<i>A</i> <sub>2</sub>	<b>x</b> 0	dx	$R^2$
IgG					
calibration	$-1.20 \times 10^{-4}$	1.91× 10 <sup>-6</sup>	$-1.15 \times 10^{4}$	$2.75 \times 10^{3}$	0.981
curve					
IgM					
calibration	$-2.79 \times 10^{-4}$	$1.68 \times 10^{-6}$	$-4.29 \times 10^{4}$	$8.25 \times 10^{3}$	0.965
curve					

Positive patient samples (CoV2+)	Days since symptom onset	Average IgG test CA current (µA)	IgG concentrati on (ng/mL)	Average IgM test CA current (µA)	IgM concentrati on (ng/mL)
p1	33	0.503	731	0.297	915
p2	33	0.266	297	0.265	726
p3	33	0.953	1800	0.27	758
p4	33	1.23	2760	0.275	786
p5	34	1.11	2300	0.564	2690
p6	34	0.99	1910	0.401	1560
p7	34	0.479	683	0.309	987
p8	33	0.47	666	0.468	2010
p9	34	0.491	707	0.29	876
p10	34	0.823	1450	0.492	2180
p11	34	1.49	4060	0.161	141
p12	8	0.357	455	0.988	6640
p13	1	0.182	159	0.136	4.41
p14	4	0.638	1010	0.250	641
p15	33	0.416	564	0.184	265
p16	33	0.333	414	0.582	2830
p17	33	0.929	1730	0.522	2380
p18	9	0.694	1130	0.457	1940
p19	30	0.336	419	0.222	479
p20	35	1.09	2230	0.824	4890
Negative patient samples (CoV2-)					
nl	N/A	0.129	N/A	0.135	N/A
n2	N/A	0.0715	N/A	0.167	N/A
n3	N/A	0.132	N/A	0.165	N/A
n4	N/A	0.154	N/A	0.148	N/A
n5	N/A	0.144	N/A	0.180	N/A
n6	N/A	0.0683	N/A	0.171	N/A
n7	N/A	0.0865	N/A	0.068	N/A
n8	N/A	0.168	N/A	0.157	N/A
n9	N/A	0.171	N/A	0.144	N/A
n10	N/A	0.152	N/A	0.142	N/A

•

 Table S3 Testing results of five-fold-diluted human serum samples.